Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral response.
Adjuvant System
Immune response
Plasmacytoid dendritic cells
Toll-like receptor 7
Type I interferon
Vaccine
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
16 01 2023
16 01 2023
Historique:
received:
08
06
2022
revised:
29
11
2022
accepted:
05
12
2022
pubmed:
24
12
2022
medline:
4
1
2023
entrez:
23
12
2022
Statut:
ppublish
Résumé
The candidate Adjuvant System AS37 contains a synthetic toll-like receptor agonist (TLR7a) adsorbed to alum. In a phase I study (NCT02639351), healthy adults were randomised to receive one dose of licensed alum-adjuvanted meningococcal serogroup C (MenC-CRM
Identifiants
pubmed: 36564274
pii: S0264-410X(22)01519-5
doi: 10.1016/j.vaccine.2022.12.006
pii:
doi:
Substances chimiques
Aluminum Hydroxide
5QB0T2IUN0
aluminum sulfate
34S289N54E
Interferons
9008-11-1
Toll-Like Receptor 7
0
Antiviral Agents
0
Vaccines, Conjugate
0
Meningococcal Vaccines
0
Adjuvants, Immunologic
0
Cytokines
0
TLR7 protein, human
0
Banques de données
ClinicalTrials.gov
['NCT02639351']
Types de publication
Randomized Controlled Trial
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
724-734Informations de copyright
Copyright © 2022 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Emilio Siena reports financial support was provided by GSK. Francesca Schiavetti reports financial support was provided by GSK group of companies. Erica Borgogni reports financial support was provided by GSK. Marianna Taccone reports financial support was provided by GSK. Elisa Faenzi reports financial support was provided by GSK. Michela Brazzoli reports financial support was provided by GSK. Susanna Aprea reports financial support was provided by GSK. Monia Bardelli reports financial support was provided by GSK group of companies. Gianfranco Volpini reports financial support was provided by GSK. Francesca Buricchi reports financial support was provided by GSK. Chiara Sammicheli reports financial support was provided by GSK. Simona Tavarini reports financial support was provided by GSK. Viviane Bechtold reports financial support was provided by GSK. Christoph J. Blohmke reports financial support was provided by GSK. Carlo De Intinis reports financial support was provided by GSK. Antonio Gonzalez-Lopez reports financial support was provided by GSK. Derek T. O Hagan reports financial support was provided by GSK. Sandra Nuti reports financial support was provided by GSK. Claudia Seidl reports financial support was provided by GSK. Arnaud M Didierlaurent reports financial support was provided by GSK. Sylvie Bertholet reports financial support was provided by GSK. Ugo D Oro reports financial support was provided by GSK. Duccio Medini reports financial support was provided by GSK. Oretta Finco reports financial support was provided by GSK. Ugo D Oro reports a relationship with GSK that includes: equity or stocks. Christoph J. Blohmke reports a relationship with GSK that includes: equity or stocks. Derek T. O Hagan reports a relationship with GSK that includes: equity or stocks. Sylvie Bertholet reports a relationship with GSK that includes: equity or stocks. Derek T O Hagan has patent issued to Alum/TLR7. Ugo D Oro and Sylvie Bertholet are listed as inventor on patents owned by the GSK. Arnaud M Didierlaurent reports personal fees from Speranza and Lubrizol for consultancy, outside the submitted work. All authors declare no other financial or non-financial relationships and activities.